Inhibition of Ejaculation by the Non-peptide Oxytocin Receptor Antagonist GSK557296: a Multi-level Site of Action

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2013 Mar 28

PMID 23530818

Citations 13

Authors

Pierre Clement

Jacques Bernabe

Sandrine Compagnie

Laurent Alexandre

Stewart McCallum

Francois Giuliano

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Oxytocin (OT) plays a major role in the control of male sexual responses. Notably, blockade of OT receptors has been reported to inhibit ejaculation in animals. The study aimed to investigate the action of a highly selective, non-peptide OT antagonist GSK557296 in a model of pharmacologically induced ejaculation in anaesthetized rats. The site of action was assessed by investigating different delivery routes for this compound.

Experimental Approach: Urethane-anaesthetized Wistar rats were implanted with a cerebral ventricle cannula for i.c.v. injections or with a subdural catheter for intrathecal (i.t.) GSK557296 injections. Occurrence of ejaculation was assessed following i.v. 7-hydroxy-2-(di-N-propylamino)tetralin (7-OH-DPAT), a dopamine D3 receptor agonist. In addition, seminal vesicle pressures (SVP) and bulbospongiosus muscle (BS) EMG were recorded as physiological markers of emission and expulsion phases of ejaculation respectively.

Key Results: Highest i.v. GSK557296 dose reduced occurrence of ejaculation and increases in SVP but had no effect on BS-EMG. I.c.v. GSK557296 dose dependently inhibited ejaculation, increases in SVP and BS contractions. At spinal thoracic level, GSK557296 dose dependently inhibited ejaculation and increases in SVP but BS-EMG was impaired only with the highest dose. When delivered at lumbar level, GSK557296 dose dependently inhibited ejaculation, increases in SVP and BS contractions.

Conclusions And Implications: In the 7-OH-DPAT-induced ejaculation model, GSK557296 acts peripherally and centrally to inhibit ejaculation with different modalities. Blockade of brain OT receptors seems to be the most effective mechanism of action. Targeting central OT receptors with highly selective antagonist seems a promising approach for the treatment of premature ejaculation.

Citing Articles

Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.

Hassan M, Flanagan T, Eshaq A, Altamimi O, Altalag H, Alsharif M Cancers (Basel). 2025; 17(5).

PMID: 40075690 PMC: 11898507. DOI: 10.3390/cancers17050843.

Current and emerging treatment options for premature ejaculation.

Gul M, Bocu K, Serefoglu E Nat Rev Urol. 2022; 19(11):659-680.

PMID: 36008555 DOI: 10.1038/s41585-022-00639-5.

Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances.

Melis M, Argiolas A Int J Mol Sci. 2021; 22(19).

PMID: 34638719 PMC: 8509000. DOI: 10.3390/ijms221910376.

Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Stadler B, Whittaker M, Exintaris B, Middendorff R Front Endocrinol (Lausanne). 2020; 11:565731.

PMID: 33193084 PMC: 7642622. DOI: 10.3389/fendo.2020.565731.

The Sexual Motivation of Male Rats as a Tool in Animal Models of Human Health Disorders.

Bialy M, Bogacki-Rychlik W, Przybylski J, Zera T Front Behav Neurosci. 2020; 13:257.

PMID: 31956302 PMC: 6947634. DOI: 10.3389/fnbeh.2019.00257.

References

Pattij T, de Jong T, Uitterdijk A, Waldinger M, Veening J, Cools A . Individual differences in male rat ejaculatory behaviour: searching for models to study ejaculation disorders. Eur J Neurosci. 2005; 22(3):724-34. DOI: 10.1111/j.1460-9568.2005.04252.x. View

Simerly R, Swanson L . Projections of the medial preoptic nucleus: a Phaseolus vulgaris leucoagglutinin anterograde tract-tracing study in the rat. J Comp Neurol. 1988; 270(2):209-42. DOI: 10.1002/cne.902700205. View

Clement P, Bernabe J, Denys P, Alexandre L, Giuliano F . Ejaculation induced by i.c.v. injection of the preferential dopamine D(3) receptor agonist 7-hydroxy-2-(di-N-propylamino)tetralin in anesthetized rats. Neuroscience. 2007; 145(2):605-10. DOI: 10.1016/j.neuroscience.2006.12.003. View

Elands J, Beetsma A, Barberis C, de Kloet E . Topography of the oxytocin receptor system in rat brain: an autoradiographical study with a selective radioiodinated oxytocin antagonist. J Chem Neuroanat. 1988; 1(6):293-302. View

Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010; 160(7):1577-9. PMC: 2936830. DOI: 10.1111/j.1476-5381.2010.00872.x. View

Stoneham M, Everitt B, Hansen S, Lightman S, Todd K . Oxytocin and sexual behaviour in the male rat and rabbit. J Endocrinol. 1985; 107(1):97-106. DOI: 10.1677/joe.0.1070097. View

Argiolas A, Collu M, Gessa G, Melis M, Serra G . The oxytocin antagonist d(CH2)5Tyr(Me)-Orn8-vasotocin inhibits male copulatory behaviour in rats. Eur J Pharmacol. 1988; 149(3):389-92. DOI: 10.1016/0014-2999(88)90675-9. View

Arletti R, Bazzani C, Castelli M, Bertolini A . Oxytocin improves male copulatory performance in rats. Horm Behav. 1985; 19(1):14-20. DOI: 10.1016/0018-506x(85)90002-9. View

Giuliano F, Clement P . Neuroanatomy and physiology of ejaculation. Annu Rev Sex Res. 2006; 16:190-216. View

10.

Borthwick A, Liddle J, Davies D, Exall A, Hamlett C, Hickey D . Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. J Med Chem. 2012; 55(2):783-96. DOI: 10.1021/jm201287w. View

11.

Sasek C, Seybold V, Elde R . The immunohistochemical localization of nine peptides in the sacral parasympathetic nucleus and the dorsal gray commissure in rat spinal cord. Neuroscience. 1984; 12(3):855-73. DOI: 10.1016/0306-4522(84)90175-1. View

12.

Borgdorff A, Bernabe J, Denys P, Alexandre L, Giuliano F . Ejaculation elicited by microstimulation of lumbar spinothalamic neurons. Eur Urol. 2008; 54(2):449-56. DOI: 10.1016/j.eururo.2008.03.043. View

13.

Maggi M, Malozowski S, Kassis S, Guardabasso V, Rodbard D . Identification and characterization of two classes of receptors for oxytocin and vasopressin in porcine tunica albuginea, epididymis, and vas deferens. Endocrinology. 1987; 120(3):986-94. DOI: 10.1210/endo-120-3-986. View

14.

Carmichael M, HUMBERT R, Dixen J, Palmisano G, Greenleaf W, Davidson J . Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab. 1987; 64(1):27-31. DOI: 10.1210/jcem-64-1-27. View

15.

Clement P, Peeters M, Bernabe J, Denys P, Alexandre L, Giuliano F . Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-N-propylamino) tetralin (7-OH-DPAT) in anaesthetized rats. Br J Pharmacol. 2008; 154(5):1150-9. PMC: 2451048. DOI: 10.1038/bjp.2008.176. View

16.

Luiten P, Ter Horst G, Karst H, Steffens A . The course of paraventricular hypothalamic efferents to autonomic structures in medulla and spinal cord. Brain Res. 1985; 329(1-2):374-8. DOI: 10.1016/0006-8993(85)90554-2. View

17.

Kitrey N, Clement P, Bernabe J, Alexandre L, Giuliano F . Microinjection of the preferential dopamine receptor D3 agonist 7-hydroxy-N,N-di-n-propylaminotetralin hydrobromide into the hypothalamic medial preoptic area induced ejaculation in anesthetized rats. Neuroscience. 2007; 149(3):636-41. DOI: 10.1016/j.neuroscience.2007.06.051. View

18.

Truitt W, Coolen L . Identification of a potential ejaculation generator in the spinal cord. Science. 2002; 297(5586):1566-9. DOI: 10.1126/science.1073885. View

19.

Filippi S, Vannelli G, Granchi S, Luconi M, Crescioli C, Mancina R . Identification, localization and functional activity of oxytocin receptors in epididymis. Mol Cell Endocrinol. 2002; 193(1-2):89-100. DOI: 10.1016/s0303-7207(02)00101-6. View

20.

Giuliano F, Clement P . Pharmacology for the treatment of premature ejaculation. Pharmacol Rev. 2012; 64(3):621-44. DOI: 10.1124/pr.111.004952. View